Lung Cancer

A benzodiazepine analog produced positive results in a mouse study.

Black patients are less likely than White patients to get the molecular testing that can led to immunotherapy and other more advanced treatments.

Libtayo monotherapy nearly doubled the median overall survival and lowered the risks of death and disease progression.

The data revealed that 17.1% of patients experienced grade 3 or greater arrhythmias.

Researchers that clinical guidelines highlight the possibility of chronic obstructive pulmonary disease and other conditions masking early symptoms of lung cancer.

One of the biggest misconceptions about lung cancer is that it only affects smokers, according to Amy Moore, vice president of Global Engagement and Research Partnerships at LUNGevity.

Obesity is an important modifiable risk factor for developing cancer, second only to tobacco use. Obesity is traditionally defined as having a body mass index (BMI) of 30 kg/m2 or greater, while a BMI of 25 up to 30 kg/m2 is considered overweight.

A recent study highlights a concerning association between missed follow-up appointments and an increased risk of death in people diagnosed with stage I non-small cell lung cancer.

The objective of the study was to project the life-years (LYs) and quality-adjusted LYs for patients eligible for Vitrakvi compared to those receiving a checkpoint inhibitor, Opdivo (nivolumab) or Keytruda (pembrolizumab).

Researchers from the University of Utah in Salt Lake City have developed a more comprehensive, multifaceted digital tool for lung cancer screening that integrates into EHR as well as patient portals. Their paper was published in JAMA Network Open in June 2024.

In a randomized clinical trial, the effectiveness of a stepped-care model for delivering palliative care to patients with advanced lung cancer was evaluated.

Researchers evaluated the association between body composition from readouts generated by cross-sectional imaging and oncologic outcomes in patients with advanced or metastatic NSCLC treated with systemic immunotherapy.

The study evaluated the efficacy and safety of Dato-DXd compared to docetaxel in adult patients with locally advanced or metastatic NSCLC with and without actionable genomic alterations who require systemic therapy following prior treatment.

First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.

According to a recent study in JAMA Network Open, robotic-assisted lung surgeries take a bit longer but seem to be just as safe as video-assisted surgeries.

Cancer patients not only experience the physical and mental toll of treatments like chemotherapy but also face "financial toxicity" due to high out-of-pocket costs, which can challenge their ability to work.

A group of researchers recently aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.

The term "time toxicity" has been coined for the large amounts of time taken up healthcare that may interfere with other priorities.

Enhertu demonstrated antitumor activity against HER2-overexpressing metastatic NSCLC in the trial.

In the U.S., nearly 200,000 new cases of lung cancer were reported in 2020, with over 100,000 deaths. While the number of lung cancer deaths has generally decreased over the past 20 years, lung cancer remains the leading cause of cancer deaths in the US and is the third most common type of cancer.

Initial treatments for lung adenocarcinomas may be effective at first, but sometimes these tumors can respond by turning into small cell lung cancer (SCLC), a more aggressive and difficult-to-treat disease.

It is well-known that smoking is linked to a higher risk of cancer, and those who smoke can lower their risk by quitting. However, it remains unclear exactly how many years of continued smoking cessation are needed to see a substantial risk reduction.

Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.

Post-operative mortality rates decreased 30 and 90 days after surgery.

While tissue biopsy is currently recommended as the gold standard for determining mutations in non-small cell lung cancer, its success is not guaranteed, prompting the consideration of the liquid biopsy method as a viable alternative.